228760.KS KSC
Genomictree Inc
1W: +1.9%
1M: -22.0%
3M: +51.1%
1Y: +27.4%
3Y: -7.3%
5Y: -24.6%
₩21,100.00
Last traded 2024-08-14 — delisted
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$2.4B
-30.9% ▼
5Y CAGR: +53.0%
Gross Profit
-$727M
-169.1% ▼
Operating Income
-$15.3B
+11.5% ▲
Net Income
-$10.2B
-17.0% ▼
EPS (Diluted)
$-432.48
-7.5% ▼
EBITDA
-$8.9B
-41.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $5.1B | $29.9B | $3.4B | $2.4B |
| YoY Growth | +339.9% | +314.9% | +481.1% | -88.6% | -30.9% |
| Cost of Revenue | $1.2B | $2.6B | $4.9B | $3.7B | $3.1B |
| Gross Profit | $55M | $2.5B | $25.0B | -$270M | -$727M |
| Gross Margin | 4.5% | 48.9% | 83.7% | -7.9% | -30.8% |
| R&D Expenses | $3.5B | $2.8B | $5.4B | $4.4B | $4.9B |
| SG&A Expenses | $3.9B | $3.3B | $9.0B | $2.9B | $2.5B |
| Operating Expenses | $12.5B | $12.4B | $22.6B | $17.0B | $14.6B |
| Operating Income | -$12.4B | -$9.9B | $8.9B | -$17.3B | -$15.3B |
| Operating Margin | -1001.6% | -191.7% | 29.8% | -506.2% | -648.2% |
| Interest Expense | $1.7B | $4.6B | $5.4B | $2.1B | $295M |
| Income Before Tax | -$11.7B | -$11.4B | -$3.7B | -$9.5B | -$10.4B |
| Tax Expense | $944K | $916K | $2.5B | -$497M | $1M |
| Net Income | -$11.7B | -$11.4B | -$6.2B | -$8.8B | -$10.2B |
| Net Margin | -946.3% | -222.3% | -20.9% | -256.2% | -433.6% |
| EPS (Diluted) | $-586.41 | $-553.00 | $-297.25 | $-402.32 | $-432.48 |
| EBITDA | -$9.1B | -$5.8B | $3.0B | -$6.3B | -$8.9B |
| Shares Outstanding | 20M | 21M | 21M | 22M | 24M |